Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ANIP - ANI Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$99.50
DETAILS
HIGH:
$119.00
LOW:
$85.00
MEDIAN:
$97.00
CONSENSUS:
$99.50
UPSIDE:
37.64%
Stock News
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Head to Head Comparison: ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH)
Talphera (NASDAQ: TLPH - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends. Analyst Recommendations This is a summary of current
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build
ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is expected to comprise nearly 60% of 2026 revenue. Cortrophin guidance was lowered by ~$30M, but H2 expectations remain intact, with Q4 growth hinging on gout salesforce productivity.
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI's Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®.
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Contrasting ANI Pharmaceuticals (NASDAQ:ANIP) and Cumberland Pharmaceuticals (NASDAQ:CPIX)
Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation. Analyst Ratings This is a breakdown of
ANI Pharmaceuticals to Present at September Investor Conferences
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in fireside chats at the following upcoming investor conferences:
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026.
Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP
Aurora Investment Counsel bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) in the undefined quarter, according to its most recent filing with the SEC. The fund bought 26,890 shares of the specialty pharmaceutical company's stock, valued at approximately $2,226,000. Aurora Investment Counsel owned 0.12% of ANI Pharmaceuticals at the end of
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ANI Pharmaceuticals Q2 Earnings Call Highlights
ANI Pharmaceuticals NASDAQ: ANIP reported record second-quarter revenue and adjusted EBITDA as growth in its Cortrophin Gel rare-disease franchise and generics business lifted results, while the company modestly reduced its full-year Cortrophin revenue outlook to reflect first-half performance.
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $1.8 per share a year ago.
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin ® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year Quarterly GAAP net income available to common shareholders of $24.7 million; Quarterly adjusted non-GAAP EBITDA of $71.6 million, an increase of 32.4% year-over-year Diluted GAAP income per share of $1.05 and adjusted non-GAAP diluted earnings per share of $2.21 Reaffirming 2026 guidance for total net revenue of $1,080 - $1,140 million and adjusted non-GAAP EBITDA of $285 - $300 million PRINCETON, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2026.
Price Targets
ANI Pharmaceuticals initiated with a Perform at Oppenheimer
$85.00
(was $77.91)
Les Sulewski
·
Oppenheimer
ANI Pharmaceuticals initiated with an Outperform at Leerink
$104.00
(was $70.32)
Daniel Clark
·
Leerink Partners
ANI Pharmaceuticals (ANIP) PT Lowered to $119 at Guggenheim
$119.00
(was $78.25)
Vamil Divan
·
Guggenheim
ANI Pharmaceuticals price target lowered to $90 from $91 at Canaccord
$90.00
(was $78.25)
Canaccord Genuity
ANI Pharmaceuticals initiated with a Hold at Canaccord
$91.00
(was $81.92)
Canaccord Genuity
ANI Pharmaceuticals (ANIP) PT Raised to $124 at Guggenheim
$124.00
(was $85.29)
Vamil Divan
·
Guggenheim
ANI Pharmaceuticals price target raised to $90 from $77 at Truist
$90.00
(was $91.63)
Truist Financial
ANI Pharmaceuticals price target raised to $121 from $93 at H.C. Wainwright
$121.00
(was $95.36)
Brandon Folkes
·
H.C. Wainwright
ANI Pharmaceuticals price target raised to $114 from $86 at Guggenheim
$114.00
(was $95.20)
Vamil Divan
·
Guggenheim
ANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler
$94.00
(was $81.13)
David Amsellem
·
Piper Sandler
ANI Pharmaceuticals price target raised to $86 from $84 at Guggenheim
$86.00
(was $59.68)
Guggenheim
ANI Pharmaceuticals price target raised to $83 from $81 at Raymond James
$83.00
(was $61.23)
Gary Nachman
·
Raymond James
ANI Pharmaceuticals downgraded to Hold from Buy at Truist
$60.00
(was $55.48)
Les Sulewski
·
Truist Financial
ANI Pharmaceuticals (ANIP) PT Raised to $94 at H.C. Wainwright
$94.00
(was $65.49)
Oren Livnat
·
H.C. Wainwright
ANI Pharmaceuticals (ANIP) PT Raised to $87 at H.C. Wainwright
$87.00
(was $68.06)
Oren Livnat
·
H.C. Wainwright
Raymond James Maintains Outperform on ANI Pharmaceuticals, Raises Price Target to $48
$48.00
(was $34.87)
Raymond James